<DOC>
	<DOCNO>NCT01333423</DOCNO>
	<brief_summary>The goal clinical research study find high tolerable dose seliciclib give combination liposomal doxorubicin patient metastatic breast cancer .</brief_summary>
	<brief_title>Maximum Tolerated Dose ( MTD ) Liposomal Doxorubicin Combination With Seliciclib Patients With Metastatic Triple Negative Breast Cancer ( TNBC )</brief_title>
	<detailed_description>The Study Drugs : Seliciclib design stop cancer cell divide , may cause die . Doxorubicin chemotherapy drug design stop growth cancer cell , may cause cell die . Liposomal doxorubicin redesign version doxorubicin . The drug , doxorubicin , enclose fat bubble call liposome . This design allow drug get tumor tissue well stay body long time . Study Groups : If find eligible take part study , assign dose level seliciclib base join study . Up 6 dose level seliciclib test . At least 2 participant enrol dose level . The first group participant receive low dose level . Each new group receive high dose group , intolerable side effect see . This continue high tolerable dose seliciclib find . All participant receive dose level liposomal doxorubicin . Drug Administration : You take seliciclib mouth cup ( 8 ounce ) water twice day Days 1-3 28-day study cycle . The 2 dos take 12 hour apart . Seliciclib take 1 hour 2 hour meal . If miss dose , take 2 hour schedule time . If 2 hour , miss dose take . You resume take study drug next normally schedule time . You receive liposomal doxorubicin vein 2-3 hour Day 4 cycle . On Days 5-28 receive study drug . Study Visits : At study visit , ask side effect may drug may take . On Day 1 every cycle : - You physical exam , include measurement weight vital sign . - Your performance status record . - Blood ( 1-2 teaspoon ) urine collect routine test . During Week 2 Cycle 1 : -Blood ( 1-2 teaspoon ) draw routine test . You ECHO MUGA scan least every 4 cycle check heart function . After every even-numbered cycle ( Cycles 2 , 4 , 6 ) , either CT MRI scan check status disease . Length Study : You may continue take study drug long doctor think best interest . You longer able take study drug disease get bad , intolerable side effect occur , unable follow study direction . Your participation study complete end-of-study visit . End-of-Study Visit : About 4-6 week stop receive study drug , end-of-study visit . The following test procedure perform : - You physical exam , include measurement weight vital sign . - Your performance status record . - Blood ( 1-2 teaspoon ) urine collect routine test . - You ask symptom may drug may take . This investigational study . Seliciclib FDA-approved commercially available . It currently use research purpose . Liposomal doxorubicin FDA-approved commercially available metastatic breast cancer . The use drug together investigational . Up 40 patient take part study . All enrol M. D. Anderson .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Triple Negative Breast Neoplasms</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Roscovitine</mesh_term>
	<criteria>1 . Both male female patient invasive cancer confirm ER/PR/HER2 negative carcinoma breast locally advanced stage IV disease amenable curative therapy . For purpose study , triple negative disease tumor ER/PR &lt; 10 % HER2 &lt; /=1+ IHC HER2 FISH nonamplified ( ratio &lt; 2.0 ) . 2 . Patients must ECOG performance status 0 , 1 2 3 . Age &gt; /= 18 year 4 . Women must pregnant lactate teratogenic potential drug . All female childbearing potential ( i.e . A female free menses &gt; 1 year surgically sterilize ) must blood test urine study within 2 week prior start therapy rule pregnancy . 5 . Women childbearing potential ( i.e . A female free menses &gt; 1 year surgically sterilize ) strongly advise use accept effective nonhormonal method contraception . 6 . Must least one site objective measurable evaluable disease . Baseline measurement evaluation must obtain within 4 week start therapy . 7 . Patients must disease free prior malignancy &gt; /= 5 year exception curatively treat squamous cell carcinoma skin carcinoma situ cervix breast . 8 . Patients must serious medical illness , treat study , would limit survival le 1 month psychiatric illness would limit informed consent . 9 . Patients must peripheral neuropathy &gt; grade 2 . 10 . Required Cardiac Parameters : Patients must history New York Heart Association class 3 4 heart failure , history myocardial infarction , unstable angina CVA within 6 month protocol registration . LVEF &gt; 50 % MUGA ECHO . 11 . Patients must history PR prolongation AV block 12 . Required laboratory parameter : Patients must serum creatinine &lt; 1.5 mg/dl . 13 . Patients must adequate hematologic function : granulocyte &gt; 1500/mm^3 platelet &gt; 100,000/mm^3 14 . Patients must adequate hepatocellular function : SGOT ( AST ) SGPT ( ALT ) &lt; 1.5 x upper limit normal ( unless liver involved tumor , case SGOT ( AST ) SGPT ( ALT ) &lt; 2.0 x upper limit normal ) 15 . Patients must history prior therapy seliciclib . 16 . Patients must receive cumulative dose doxorubicin great 360 mg/m^2 epirubicin great 640 mg/m^2 . Patients receive &gt; 240 mg/m^2 doxorubicin &gt; 400 mg/m^2 epirubicin advise undergo evaluation leave ventricular ejection fraction ( LVEF ) echocardiogram ( ECHO ) gate heart scan ( MUGA ) prior initiate therapy . 17 . Concurrent use hormonal therapy permit . Concurrent radiation therapy permit . 18 . Patients must prior organ allograft require immunosuppressive therapy . 19 . Patients must complete recovered effect prior chemotherapy ( &lt; /= grade 2 toxicity ) . 20 . Patients must receive least one prior chemotherapy regimen metastatic disease . Progression within 6 month adjuvant chemotherapy consider equivalent one prior chemotherapy metastatic disease . 1 ) None .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2012</verification_date>
	<keyword>Breast Cancer</keyword>
	<keyword>Metastatic Triple Negative</keyword>
	<keyword>ER/PR/HER2 negative</keyword>
	<keyword>Locally advanced</keyword>
	<keyword>Stage IV</keyword>
	<keyword>Metastatic</keyword>
	<keyword>Seliciclib</keyword>
	<keyword>Liposomal Doxorubicin</keyword>
	<keyword>Doxil</keyword>
	<keyword>Doxorubicin Hydrochloride ( Liposomal )</keyword>
</DOC>